Sino Medical Sciences Technology In

Tiantong Corporation plans to invest 434 million yuan through a wholly-owned subsidiary to build an intelligent manufacturing project with an annual output of 14,600 tonnes of high-end soft magnetic new materials, with a construction period of about 36 months. Zhonghong Medical's net profit attributable to the parent company in the first half of the year surged 2662.38% year-on-year to 159 million yuan. In addition, several companies released half-year reports, with Hangzhou Cable, Yahua Group, and Yongtai Technology all posting substantial net profit growth. Jingsheng Co.'s self-developed large-size CVD SiC chemical vapour deposition coating complete equipment has passed factory inspection and been delivered to customers. Sino Medical's H-share issuance is being filed with the China Securities Regulatory Commission and is expected to be completed in the first quarter of next year; its HT Supreme drug-eluting stent system has been approved in Paraguay. Institutional seats made net purchases of 656 million yuan in Hengtong Optic-Electric and 168 million yuan in Yangtze Optical Fibre and Cable. Wanxun Automation has made progress in its domestic and overseas semiconductor business layout, and Shandong Haode and Anhui Kaize, controlled by Intco Medical, delivered excellent second-quarter profits.

Sino Medical's coronary artery spinous balloon dilatation catheter has been approved by the Ministry of Health of Vietnam. The product is used to dilate coronary artery stenosis. This overseas registration approval is an important part of the company's overseas business expansion and will promote overseas sales of the product. In the first quarter of 2026, Sino Medical achieved revenue of 140 million yuan and a net profit attributable to the parent company of 24.46 million yuan.

CATL announced plans to use no less than 20 billion yuan and no more than 40 billion yuan of its own or self-raised funds to repurchase A-shares, with a maximum buyback price of 573 yuan per share. The repurchased shares will be cancelled to reduce registered capital. The company also disclosed that in the first half of 2026, it achieved operating revenue of 276.917 billion yuan, up 54.8 percent year on year, and net profit of 43.284 billion yuan, up 41.98 percent year on year. It plans to distribute a cash dividend of 14.11 yuan for every 10 shares. Sinomed expects net profit of 50.33 million yuan in the first half of 2026, an increase of 36.49 million yuan from the same period last year, representing a 263.66 percent year-on-year rise, mainly driven by volume growth in its coronary and neurological business segments. State Grid completed cumulative fixed-asset investment of over 310 billion yuan in the first half of 2026, up 12.6 percent year on year, as it accelerated construction of key projects including ultra-high voltage lines. The film Eight Immortals, co-produced by Happy Blue Ocean, has grossed 450 million yuan at the box office since its release on July 18, as of midnight on July 23, exceeding 50 percent of the company's audited operating revenue for the most recent fiscal year. Chippacking Technology said its packaging and testing orders are full, with current order backlog scheduled about 35 days out, and forecast that indicative orders can cover more than three months.

From July 23 to 24, a number of Shanghai-listed companies released positive news covering share buybacks and stake increases, upbeat earnings reports, improving operations, and interim dividends. In terms of buybacks and stake increases, 10 companies announced new buyback plans over the two days, with a combined proposed buyback cap of 1.89 billion yuan; 5 companies announced new stake increase plans, with a combined proposed increase cap of 351 million yuan. On the earnings front, about 15 Shanghai-listed companies issued positive half-year earnings reports. Among them, Orient Securities reported a 30.46% year-on-year rise in first-half net profit attributable to the parent company, EZVIZ Network grew 35.44%, and SINOMED is expected to surge 263.66%. Another three companies, including Minmetals New Energy, turned losses into profits. At the operational level, Weiming Environment Protection's subsidiary waste treatment projects saw cumulative power generation rise 8.96% year-on-year in the first half. Changhua Group received a designated development notice from a domestic new energy vehicle maker, with an estimated total sales value of about 740 million yuan over the product lifecycle. Pudong Construction saw multiple subsidiaries win major projects, with a total bid value of approximately 1.5 billion yuan. Regarding interim dividends, four Shanghai-listed companies—China Southern Power Grid Energy Storage, Zheshang Securities, China Southern Power Grid Technology, and Jinpan Technology—received interim dividend proposals or released interim dividend distribution plans. Zheshang Securities stated that its interim dividend payout ratio for this year will be no lower than its 2025 interim ratio, while Jinpan Technology's dividend amount will be no less than 30% of net profit attributable to shareholders of the listed company in the first half of 2026.

Sino Medical has issued an announcement, expecting net profit attributable to shareholders of the listed company for the first half of 2026 to be 50.33 million yuan, a year-on-year increase of 263.66%. The profit growth is mainly due to the continued volume expansion of coronary business products and significant sales growth of new neuro business products, with operating revenue rising 26.68% year-on-year. At the same time, cost control has been effective and research and development expenses have declined.